Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference
31 5월 2023 - 9:00PM
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company
advancing an oral therapeutic candidate for Pediatric Growth
Hormone Deficiency (PGHD) through Phase 2 clinical trials,
announced that the Company will participate in the 2023 BIO
International Convention held June 5-8, 2023 in Boston and the
Jefferies Healthcare Conference held June 7-9, 2023 in New York
City. Lumos Pharma management will present and host one-on-one
meetings at both conferences.
BIO International Convention: June
5th –
8th in Boston, MA
|
Live Presentation: |
Lumos Pharma Presentation – June 6th, 2:45 PM EDT |
|
1x1 Meetings: |
Registrants may schedule 1x1s
through the BIO International Convention portal |
|
|
|
Jefferies Healthcare Conference: June
7th –
9th in New York, NY
|
Live Presentation: |
Lumos Pharma Fireside Chat – June 9th, 12:45-1:10 PM EDT |
|
Webcast link: |
Here |
|
1x1 Meetings: |
Management will host one-on-one
meetings with investors on Friday, June 9th |
|
|
|
The webcast for the Jefferies Conference
fireside chat will also be found on the Company’s website under
Events & Presentations in the Investors & Media section. A
replay will be available for 90 days thereafter. Please contact
your Jefferies salesperson or Lumos Pharma Investor Relations to
schedule one-on-one meetings with the management team during the
Jefferies Healthcare Conference or thereafter.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage
biopharmaceutical company focused on the development and
commercialization of therapeutics for rare diseases. Lumos
Pharma was founded and is led by a management team with
longstanding experience in rare disease drug development. Lumos
Pharma’s lead therapeutic candidate is LUM-201, an oral growth
hormone stimulating small molecule, currently being evaluated in a
Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the
OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for
the treatment of Pediatric Growth Hormone Deficiency (PGHD). If
approved by the FDA, LUM-201 would provide an orally administered
alternative to recombinant growth hormone injections that PGHD
subjects otherwise endure for many years of treatment. LUM-201 has
received Orphan Drug Designation in both the US and EU. For more
information, please visit https://lumos-pharma.com/.
Investor & Media Contact:
Lisa MillerLumos Pharma Investor
Relations512-792-5454ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
Lumos Pharma (NASDAQ:LUMO)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Lumos Pharma (NASDAQ:LUMO)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024